About
Noninvasive Medical Devices (NIMD) is a medical device start-up company that develops localized microwave thermal ablation devices to treat cancer. Its technology is based on a noninvasive localized microwave heating applicator coupled with nanoparticles placed inside the tumor. NIMDs device is designed to deliver the lowest microwave energy and highest accuracy for cancer treatment, and may also be used to detect cancer at an early stage. Hyperthermed is the companys first compact, versatile medical device and can be used in hospitals and cancer clinics to treat specific types of cancer using localized hyperthermia. Hyperthermed selectively targets cancer cells with no damage to the surrounding healthy tissue. The product also noninvasively images and monitors the tumor temperature. NIMD is currently focusing on breast cancer treatment, but its technology may also be applicable for skin melanomas; glioblastomas; chest, tongue, head, and neck cancers; and lung cancer. The company, located in Jerusalem, is at the preclinical stage and has demonstrated its proof of concept on animals.
Funding history · 1 round · $700K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NIMD's primary focus in medical device development?
- NIMD develops localized microwave thermal ablation devices for cancer treatment, specifically focusing on breast cancer, with potential applications for other cancers like skin melanomas and lung cancer.
- What is the status of NIMD as of November 2018?
- NIMD became inactive and ceased to operate in November 2018.
- When was NIMD founded and where is it headquartered?
- NIMD was founded in January 2015 and is headquartered in Jerusalem, Israel.
- What is the name of NIMD's primary product?
- NIMD's primary product is Hyperthermed, a compact medical device for localized hyperthermia treatment of specific cancer types.
- What was NIMD's total funding raised?
- NIMD raised a total of $700,000 USD in funding.
- When did NIMD complete its last funding round?
- NIMD completed a Seed funding round in May 2015, raising $700,000 USD.
- What stage was NIMD's technology at before it ceased operations?
- NIMD's technology was at the preclinical stage, having demonstrated proof of concept on animals.
- Who is a co-founder of NIMD?
- Anan Copty, PhD, is a co-founder of NIMD.